Apimeds Pharmaceuticals US (APUS) Income from Continuing Operations (2024 - 2026)

Apimeds Pharmaceuticals US (APUS) has reported Income from Continuing Operations for 3 consecutive years, with -$9.5 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Income from Continuing Operations fell 254.86% year-over-year to -$9.5 million; the trailing twelve-month figure through Jun 2026 stood at -$21.2 million (down 469.25% YoY), and the FY2025 full-year result was -$12.1 million, down 1000.82% from the prior year.
• Income from Continuing Operations fell to -$9.5 million in Q2 2026 per APUS's latest filing, from -$7.2 million in the prior quarter.
• Across five years, Income from Continuing Operations topped out at -$296473.0 in Q1 2024 and bottomed at -$9.5 million in Q2 2026.
• Historically, Income from Continuing Operations has averaged -$2.6 million across 3 years, with a median of -$449363.0 in 2024.
• The widest YoY moves for Income from Continuing Operations: up 35.73% in 2025, down 2216.75% in 2025.
• Over 3 years, Income from Continuing Operations stood at -$311633.0 in 2024, then slumped by 2216.75% to -$7.2 million in 2025, then tumbled by 31.32% to -$9.5 million in 2026.
• According to Business Quant data, Income from Continuing Operations over the past three periods registered -$9.5 million, -$7.2 million, and -$1.8 million for Q2 2026, Q4 2025, and Q3 2025 respectively.